The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,738.50
Bid: 1,738.00
Ask: 1,738.50
Change: -1.50 (-0.09%)
Spread: 0.50 (0.029%)
Open: 1,730.00
High: 1,744.50
Low: 1,729.00
Prev. Close: 1,740.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Evraz Up On USD375 Million Return To Shareholders

Wed, 01st Apr 2015 10:42

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 WINNERS
-------
Barclays, up 3.6% at 251.25 pence, Lloyds Banking Group, up 2.0% at 80.33p, and Royal Bank of Scotland Group up 2.1% at 347.2p. The banking stocks are reversing all the losses they made on Tuesday. Morgan Stanley lifted its price target for Barclays to 333.2 pence from 315.5p, reiterating its Overweight rating, while it also raised its RBS price target to 391.6p from 375p, keeping its Equal-Weight rating. Meanwhile, Jefferies upgraded Lloyds to Hold from Underperform, saying the group's premium valuation is now supported by a progressively rising dividend.

Royal Dutch Shell 'B', up 2.2%. Reuters reports the US government upheld a 2008 lease sale in the Chukchi Sea off Alaska, meaning Shell has moved closer to returning to exploration work in the region since it lost control of the Kulluk oil rig in 2012. The Interior's Bureau of Ocean Energy Management will now consider Shell's exploration plan and will perform an environmental assessment of it, which would take at least 30 days. But Shell, in anticipation of returning to the region, has already moved rigs to Alaska, Reuters said.

Glaxosmithkline, up 2.3% at 2,144.5p. Barclays raised its price target for the pharmaceutical company to 1,840p from 1,690p, keeping its Overweight recommendation.
-------
FTSE 100 LOSERS
-------
Kingfisher, down 2.0%. The shares of the DIY retailer are down after rising 4.4% to a nine-month high on Tuesday as it reported a drop in sales and profit for its last financial year which it blamed on a slower French market and the strength of sterling, but said the new CEO plans to organise the company "very differently" to create a unified business that will share IT systems and buying and stock inventory infrastructure. Meanwhile, Nomura has cut its price target for Kingfisher to 305p from 315p, retaining its Neutral recommendation.
-------
FTSE 250 WINNERS
-------
Evraz, up 6.5%. The steel miner said it will return USD375 million to its shareholders even though its pretax loss widened in 2014 on the back of a USD1.0 billion foreign exchange loss caused by the devaluation of the rouble, saying it has "improved business prospects" in 2015. Evraz reported a pretax loss of USD1.08 billion in 2014, compared with a USD637 million loss in 2013, on the back of the substantial foreign exchange loss and an impairment charge.

Firstgroup, up 4.4%. The transport company said its trading in the fourth quarter and whole of the financial year that ended on Tuesday was in line with its expectations, with good performances in its UK bus and rail operations. FirstGroup said its UK bus business is delivering volume growth and achieving a positive yield, and it has made progress on cost-cutting efforts within the division. Separately, Panmure Gordon upgraded the transport company to Buy from Hold, cutting its price target to 120p from 140p.
-------
AIM ALL-SHARE WINNERS
-------
CEB Resources, up 70%. The natural resources focused investment company said it has sold its remaining stake in Australian Securities Exchange-listed Balamara Resources. In October, CEB Resources sold a third of its shares in Balamara for AUD350,340. Wednesday it sold its remaining stake, selling 9.8 million shares for AUD178,108, representing a much lower price compared with the sale in October last year.

Daily Internet, up 12%. The hosting and cloud infrastructure company said its expects its results for the year to the end of March be significantly improved on the prior year. It expects revenue to be ahead of market expectations and expects earnings before interest, taxation, depreciation and amortisation to be "materially ahead" of market forecasts. The company also said its Netplan Internet Solutions Ltd business has a series of contracts worth a total of GBP565,000 with a global insurance company.
-------
AIM ALL-SHARE LOSERS
-------
Amerisur Resources, off 27%. The company said its reserves and resources for its exploration and production assets in Colombia and Paraguay fell following an independent reserves report undertaken by Petrotech Engineering. The report concluded that the company's proven gross field reserves was 16.2 million barrels of oil, down from 19.8 million barrels in 2013, whilst proven plus probable gross field reserves fell to 24.6 million barrels from 32.8 million barrels.

The Real Good Food, down 14%. The company said the fall in European Union sugar prices has meant trading in its Napier Brown and Garrett Ingredients businesses has been very difficult. Napier Brown returned to profit in the second half, it said, but remains behind expectations for the year. The company said the group outside of Napier and Garrett performed ahead of expectations, with its Renshaw and Haydens businesses both performing well.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.